Dri Healthcare Trust · TSX:DHT.U
Dri Healthcare Trust — Q2 2026 Earnings Presentation
15 slides from Dri Healthcare Trust's earnings presentation, Aug 10, 2026
Slide 1: Advancing Science in the Pharmaceutical and Biotechnology Sector
Advancing Science in the Pharmaceutical and Biotechnology Sector Second Quarter 2026 Earnings Call |August 10, 2026 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by DRI Healthcare Trust (“DRI Healthcare”). Established as an unincorporated open-ended trust in Ontario, Canada, and publicly trading since its 2021 IPO, DRI Healthcare is a global leader in providing financing to advance innovation in the life science
Slide 3: Ali Hedayat, Chief Executive Officer
Ali Hedayat Chief Executive Officer DRI Healthcare 3
Slide 4: Agenda
Agenda Ali Hedayat CEO Recent Highlights Navin Jacob Portfolio Update All Q&A CIO Zaheed Mawani CFO Financial Update 4
Slide 5: Recent Highlights
Recent Highlights Portfolio Recent Unitholder Performance Events Value • Record Q2 with double-digit • Exercised Put Option on Ekterly • Q2 distribution of $0.11 per growth across Total income, for a total net repurchase price Unit Total Cash Receipts, and of ~$178 million, which Adjusted EBITDA rep
Slide 6: Navin Jacob
Navin Jacob Executive Vice President, Investments & Chief Investment Officer, DRI Healthcare 6
Slide 7: Portfolio Performance
Portfolio Performance Portfolio assets show continued growth (millions of U.S. dollars) Q2 2026 Q2 2025 % Change 1 Q1 2026 % Change 1 TOTAL CASH RECEIPTS2 $46.5 $40.2 16% $58.4 (20%) - - n/a 5.0 (100) 2.2 - n/a 1.8 18 0.1 0.1 1 1.2 (87) 1.2 1.4 (14) 1.4 (9) 8.3 9.0 (7) 8.7 (4) 0.9 1.0 (15) 1.0 (7) 3
Slide 8: Viridian (Lumvoa & elegrobart) Transaction Update
Viridian (Lumvoa & elegrobart) Transaction Update Third synthetic royalty transaction & second pre-approval transaction for DRI Product Summary Transaction Terms Product(s) Lumvoa (veligrotug) & elegrobart US Net Sales ($M) Royalty Rates (%) • Royalty rates apply to annual U.S net sales of both prod
Slide 9: Robust pipeline of over $3 billion in potential opportunities
Address important unmet needs with life-changing therapies for patients Robust pipeline of over $3 billion Marketed by leading biotech or biopharma companies in potential opportunities1 Provides strong intellectual property and regulatory protection 1. As of June 30, 2026. Represents the aggregate v
Slide 10: Zaheed Mawani
Zaheed Mawani Chief Financial Officer 10
Slide 11: Q2 2026 Financial Highlights
Q2 2026 Financial Highlights Total Cash Receipts1 Total Income Adjusted EBITDA1 $46.5 million $50.1 million $42.6 million 16% over Q2 2025 13% over Q2 2025 40% over Q2 2025 Adjusted EBITDA Margin1 Adjusted Cash Earnings per Unit1 Declared Cash Distributions per Unit 92% $0.56 $0.11 1. Total Cash Rec
Slide 12: Strong Cash Generation
Strong Cash Generation Cash available to drive portfolio growth and maintain distributions to Unitholders Adjusted EBITDA1 for the Last Twelve Months Ended June 30, 2026 (millions) LTM Adjusted EBITDA Margin1 $209.2 ($2.6) ($0.9) ($5.1) 90% ($1.4) ($0.1) $199.1 ($20.8) $178.3 Total Income Net gain (
Slide 13: Well-Capitalized for Growth
Well-Capitalized for Growth Significant capacity for Cash and cash equivalents Royalties receivable Credit facility availability further $55.2 $54.7 $519.5 growth million1 million1 million1 1. As at June 30, 2026. 13
Slide 14: Efficient Execution & Disciplined Expense Management
Efficient Execution & Disciplined Expense Management Key priorities Strengthening Asset Risk Framework Disciplined Capital Allocation Focus on long-term, sustainable growth generating strong Unitholder returns 14
Slide 15: Thank you
Thank you Contact us Bill Zhang ir@drihealthcare.com 15